Diversigen and Norgen Biotek Corp today announced that they have entered into a strategic partnership through which industry and academic researchers will benefit from comprehensive end-to-end logistical, sequencing, and analytical solutions to meet the growing needs for microbiome analyses.
Diversigen will serve as a central lab for the generation of high quality microbiome data to be incorporated into the Crohn’s & Colitis Foundation’s IBD Plexus® platform.
Phase I Clinical Trial Generates Data on Mechanism of Action, Safety and Tolerability
4D pharma plc, a pharmaceutical company focusing on the development of live biotherapeutics, today provides the following update on the phase 1 clinical trial in respect of Blautix, its proprietary single strain live biotherapeutic for the treatment of Irritable Bowel Syndrome (IBS).
Diversigen Announces Strategic Partnership with Korea-based BioCore Diversigen, Inc., the leading provider of comprehensive microbiome analysis services, today announced a strategic partnership with BioCore Co. Ltd., a leading bioanalytical contract research organization, based in Seoul, South Korea.
Diversigen Announces Strategic Partnership With Baylor Miraca Diversigen, Inc. announces a strategic partnership with Baylor Miraca Genetics Laboratories (BMGL), a global leader in genetic testing, to provide their customers access to a broad range of targeted genomics and metabolomics services. The two companies, both commercial endeavors of Baylor College of Medicine, are leveraging the scientific acumen and research infrastructure from the renowned College that founded them. Each company will provide access to the services of the other for customers interested in a greater understanding of the host-microbiome relationship.
Dr. George Gunn joins Diversigen Board of Directors Diversigen, Inc., today announced the appointment of Dr. George Gunn to the company’s Board of Directors. Dr. Gunn is renowned for his successful leadership and contributions to the global animal health and pharmaceutical industries. Until January 2015, Dr. Gunn was Division Head of Novartis Animal Health and a member of the Novartis Executive Committee.
“We believe the name Diversigen encompasses the extensive expertise that we deliver across the entire project life cycle to help our customers understand and harness the vast opportunities rapidly emerging in microbiome research,” according to Joesph F. Petrosino, PhD, Diversigen Founder and Chief Science Officer, as well as Director of the Alkek Center for Metagenomics and Microbiome Research and Associate Professor of Virology and Microbiology at Baylor College of Medicine.
Dr. Mills said that he is excited about the opportunity to help lead Metanome to the next level in its development. “Metanome is quickly making a name for itself by partnering with innovative pharmaceutical companies and providing best in class metagenomic services and data analytics, all fueled by access to the breadth and depth of microbiome research at Baylor College of Medicine.”
“Metanome, Inc. has been a valuable corporate collaborator in our studies of the human microbiome delivering high-quality, genomic data in a timely manner. I’ve appreciated their responsiveness and willingness to work with Seres Health on meeting our various genomic characterization needs and look forward to continuing to work with Metanome to support our future sequencing efforts.” – Dr. Matthew Henn, Head of Therapeutic Design at Seres Health